Gel Formulation Designed for Less Frequent Injection Regimen
AIV007 is a novel formulation using our JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFβ1 mRNA expression and TGFβ1 levels to reduce collagen production and scarring.
AIV007 is currently being developed for neovascular macular degeneration (nAMD), benign prostatic hyperplasia (BPH), and certain solid tumors. In nonclinical in vivo studies for nAMD, AIV007 demonstrated safety, efficacy, and prolonged treatment duration with a single intravitreal administration. Ocular safety and effects in the reduction of neovascularization and fibrosis were observed in several nonclinical animal models and patients.
A clinical trial for nAMD is planned in 2023. Development for BPH and solid tumors is in preclinical development.